Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway
Jun Yang
Topics & Concepts
Cancer researchNeuroblastomaMechanism of actionDrugMedicinePanobinostatBiologyBioinformaticsPharmacologyGeneticsGeneCell cultureHistoneHistone deacetylaseIn vitroNeuroblastoma Research and TreatmentsCancer, Hypoxia, and MetabolismNeonatal Health and Biochemistry